Log in

NASDAQ:LPTXLeap Therapeutics Stock Price, Forecast & News

-0.04 (-1.41 %)
(As of 06/4/2020 04:00 PM ET)
Today's Range
Now: $2.80
50-Day Range
MA: $2.19
52-Week Range
Now: $2.80
Volume485,600 shs
Average Volume348,251 shs
Market Capitalization$100.24 million
P/E RatioN/A
Dividend YieldN/A
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Read More
Leap Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:LPTX



Sales & Book Value

Annual SalesN/A
Book Value($0.07) per share


Net Income$-32,900,000.00


Market Cap$100.24 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

How has Leap Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LPTX shares have increased by 39.3% and is now trading at $2.80. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Leap Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Leap Therapeutics.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Leap Therapeutics.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.31. The company had revenue of $0.38 million for the quarter. View Leap Therapeutics' earnings history.

What price target have analysts set for LPTX?

3 Wall Street analysts have issued 12 month price targets for Leap Therapeutics' stock. Their forecasts range from $2.50 to $6.00. On average, they anticipate Leap Therapeutics' stock price to reach $4.50 in the next year. This suggests a possible upside of 60.7% from the stock's current price. View analysts' price targets for Leap Therapeutics.

Has Leap Therapeutics been receiving favorable news coverage?

News headlines about LPTX stock have trended extremely negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Leap Therapeutics earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutLeap Therapeutics.

Are investors shorting Leap Therapeutics?

Leap Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,430,000 shares, an increase of 32.4% from the April 30th total of 1,080,000 shares. Based on an average daily trading volume, of 436,600 shares, the days-to-cover ratio is presently 3.3 days. Approximately 6.7% of the company's shares are short sold. View Leap Therapeutics' Current Options Chain.

Who are some of Leap Therapeutics' key competitors?

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Amarin (AMRN), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), Verastem (VSTM), Clearside Biomedical (CLSD), Genocea Biosciences (GNCA) and ImmunoGen (IMGN).

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the following people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63)

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (18.79%), Perceptive Advisors LLC (18.79%), Sphera Funds Management LTD. (1.68%), Personal CFO Solutions LLC (0.18%), BlackRock Inc. (0.11%) and MYDA Advisors LLC (0.08%). View institutional ownership trends for Leap Therapeutics.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Sphera Funds Management LTD., Personal CFO Solutions LLC, MYDA Advisors LLC, Gratus Capital LLC, and BlackRock Inc.. View insider buying and selling activity for Leap Therapeutics.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $2.80.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $100.24 million. The company earns $-32,900,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is www.leaptx.com.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.